Switch: attack reduction
Switch: attack reduction Patient preference Disease control
Concrete wall with an illuminated switch. Concrete wall with an illuminated switch.

Switch Patients Switching HAE treatments may be worth it

pipe
Switch: attack reduction

In the open-label study

Switching to DAWNZERA reduced mean HAE attack rate by 62% from prior treatment

Results in patients who switched to DAWNZERA every 4 weeks from an interim analysis at Week 161 *

Exploratory endpoint: reductions in mean monthly HAE attack rate with DAWNZERA1
Graph showing reductions in mean monthly HAE attack rate with DAWNZERA from prior LTP treatment baseline. Graph showing reductions in mean monthly HAE attack rate with DAWNZERA from prior LTP treatment baseline.
*

Baseline monthly HAE attack rate established in the 10-week screening period.1

  • These are not head-to-head data. Findings are from an open-label, uncontrolled safety study in patients who wanted to switch to DAWNZERA, and was not powered for any comparisons between prior treatment groups; thus, these observations cannot be generalized to other patients on prior long-term prophylactic treatments
  • The majority of adverse events were mild to moderate and consistent with the placebo-controlled study1,2
cirlce-desktop circle-mobile
Patient preference

In the open-label study

Majority of patients who switched reported they preferred DAWNZERA

Patients successfully transitioned to DAWNZERA every 4 weeks from lanadelumab, berotralstat, or a C1-INH with no mean loss of efficacy and no new safety signals1

Exploratory endpoint: patient preference in an interim analysis at Week 16 (n=55)1
84% of patients reported they preferred DAWNZERA.

84% of patients surveyed who switched preferred DAWNZERA, most saying it worked better to control their HAE1

Reasons patients chose for preferring DAWNZERA*:

  • 63% chose “it works better to control my HAE”
  • 65% chose “less time to administer”
  • 50% chose “less injection-site pain or reaction”
  • These are not head-to-head data. Findings are from an open-label, uncontrolled safety study in patients who wanted to switch to DAWNZERA, and was not powered for any comparisons between prior treatment groups; thus, these observations cannot be generalized to other patients on prior long-term prophylactic treatments.
*

More than 1 reason was permitted.1

pipe
Disease control

In the open-label study

93% of patients reported they were well-controlled with DAWNZERA1

  • Disease control was self-reported by patients using the Angioedema Control Test (AECT)1
Mean proportion of patients well-controlled on DAWNZERA (AECT)1
Bar chart showing 93% of patients reported they were well-controlled with DAWNZERA using the AECT. Bar chart showing 93% of patients reported they were well-controlled with DAWNZERA using the AECT.
Neon lettering reading '93%'.

reported that their disease was well controlled1

Well-controlled was defined as ≥10 out of 16 possible points on the AECT3*

Scores of 0 to 9 equated to poorly-controlled angioedema

Learn more about the AECT

*The AECT was validated in 81 patients with recurrent angioedema, including 25 with HAE or acquired angioedema due to C1-INH deficiency. It was not specifically validated for HAE.3

These are not head-to-head data. Findings are from an open-label, uncontrolled safety study in patients who wanted to switch to DAWNZERA, and was not powered for any comparisons between prior treatment groups; thus, these observations cannot be generalized to other patients on prior long-term prophylactic treatments.

View switch protocol

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

References: 1. Riedl MA, Bernstein JA, Jacobs JS, et al. Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract. 2025 Jul 17:S2213-2198(25)00599-9. doi:10.1016/j.jaip.2025.06.01 2. DAWNZERA. Prescribing information. Ionis Pharmaceuticals. 3. Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test (AECT)—a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract. 2020;8(6):2050-2057.e4. doi:10.1016/j.jaip.2020.02.038 4. Data on file. Ionis Pharmaceuticals.